(Q44962394)

7 December 2017

Updated concepts and treatment of carcinoma in situ (English)

1 reference

7 December 2017

Lamm D

1

1 reference

7 December 2017

Herr H

2

1 reference

7 December 2017

Jakse G

3

1 reference

7 December 2017

Kuroda M

4

1 reference

7 December 2017

Mostofi FK

5

1 reference

7 December 2017

Okajima E

6

1 reference

7 December 2017

Sakamoto A

7

1 reference

7 December 2017

Sesterhenn I

8

1 reference

7 December 2017

da Silva FC

9

1 reference

7 December 2017

1 July 1998

1 reference

7 December 2017

1 reference

7 December 2017

4

1 reference

7 December 2017

130-138

1 reference

7 December 2017

4-5

1 reference

Carcinoma in situ of the urinary bladder. Clues to host involvement in human carcinogenesis

7 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Histological study of vesical urothelium intervening between gross neoplasms in total cystectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Intra-urothelial cancer: carcinoma in situ, Bowen's disease of the urinary system: discussion of thirty cases

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

NATURAL HISTORY AND CLINICAL BEHAVIOR OF IN SITU CARCINOMA OF THE HUMAN URINARY BLADDER

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Inflammatory carcinoma of the bladder and interstitial cystitis

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

The Masquerade of Bladder Cancer in Situ as Interstitial Cystitis

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

The Plight of the Patient with Carcinoma in Situ of the Bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Value of random endoscopic biopsy in the diagnosis of bladder carcinoma in situ

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Summary of workshop on carcinoma in situ of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Flat carcinoma in Situ of bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

5-year experience with intravesical therapy of carcinoma in situ: an inquiry into the risks of "conservative" management

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Prognostic significance of urine cytology on initial follow-up after intravesical mitomycin C for superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Topical mitomycin C therapy for carcinoma in situ of the bladder: a followup

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Phase 1/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Drug therapy of bacillus Calmette-Guérin sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Upper urinary tract transitional cell cancer after radical cystectomy for bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Upper urinary tract involvement in patients with bladder carcinoma in situ (Tis): its impact on management

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Upper tract tumors in patients with primary bladder cancer followed for 15 years

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Transitional cell carcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette-Guerin

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

BCG and cancer (first of two parts).

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guérin therapy without previous transurethral resection of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Bropirimine immunotherapy of upper urinary tract carcinoma in situ

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Chemotherapy in bladder carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Intravesical therapy with adriamycin in patients with superficial bladder tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Intracavitary doxorubicin hydrochloride therapy for carcinoma in situ of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Intravesical adriamycin therapy in carcinoma in situ of the urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Topical mitomycin C therapy for carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2899%2900020-4

7 January 2021

10.1016/S1078-1439(99)00020-4

Identifiers

DOI

1 reference

7 December 2017

1 reference